ClinicalTrials.gg
Status unknownNCT04298528dronabinolUpdated Jan 10, 2023

A RCT Comparing Dronabinol to a Placebo for Post-operative Pain in Total Joint Arthroplasty

A Phase 3 interventional study of Dronabinol and Placebo in Osteoarthritis, Knee, sponsored by Colorado Joint Replacement. Status unknown at 1 site in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-01-10.

Sponsored by Colorado Joint Replacement · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 152 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Planned enrollment
63rd of 691
460 · median 72
Started
2020
with 53 others
Phase 3
76 of 796
6 open now
Registered
511th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 63rd largest by planned enrollment of the 691 interventional ones that give a count, is one of 54 that started in 2020, is one of 76 in phase 3, and was the 511th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study was to determine if cannabinoid use decreases narcotic consumption in patients undergoing total knee arthroplasty (TKA).

Read the detailed description

Subjects enrolled will be randomized into one of two groups either receiving the study drug or a placebo and will be followed for the first 6 weeks with regards to outcomes data.

03

Conditions studied

  • Osteoarthritis, Knee
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated from
  • Stated willingness to comply with all study procedures and availability to attend all required visits for the duration of the study.
  • Male or Female
  • Age 21-75
  • Unilateral total knee arthroplasty at Colorado Joint Replacement
  • All individuals will be screened for drug use (including cannabis) at their preoperative appointment
  • Ability to take oral medication and be willing to adhere to the dronabinol regimen
  • For females of : use of highly effective for at least 1 month prior to screening and agreement to use such a method during study participation.
  • For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.

Exclusion criteria

Exclusion Criteria:

  • Narcotic use in the past 6 weeks
  • Regular cannabis use in the past 3 months
  • Major depression or anxiety disorders
  • Documented psychiatric illness (e.g. bipolar, schizophrenia)
  • Seizure disorder
  • Current or previous history of drug and alcohol abuse
  • Known allergic reactions to components of dronabinol
  • Tobacco use in the past 90 days
  • Treatment with another drug
  • Patients that cannot receive spinal anesthesia
  • Patients that cannot receive the standardized multimodal pain medications (i.e. Tylenol, gabapentin and meloxicam)
  • Patients that are not able to go home after leaving the hospital and require a short term rehabilitation facility
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
460 participants (estimated)

Study arms

  • Experimental
    dronabinol

    Patient will be directed to take 2.5mg of Study Drug 2 times a day for 4 weeks. Patient is blinded as to whether or not this is Dronabinol.

    Drug: Dronabinol

  • Placebo comparator
    placebo

    Patient will be directed to take 2.5mg of Study Drug 2 times a day for 4 weeks. Patient is blinded as to whether or not this is Dronabinol.

    Other: Placebo

Interventions

  • 2.5mg 2 times a day for 30 days after total knee replacement

    Also known as: Marinol

  • OtherPlacebo

    2 times a day for 30 days after total knee replacement

    Also known as: Lactose

06

What researchers measure

Primary outcomes

  1. Morphine Equivalence

    Morphine Equivalence of pain medication used after a total knee replacement

    Time frame: 30 day's post operative

Secondary outcomes

  1. Nausea

    Patients post operative nausea will be collected as none/mild/moderate/severe

    Time frame: 30 day's post operative

  2. Defense and Veterans Pain Scale

    Patients will keep a pain log after their joint replacement on a scale of 0 - 10

    Time frame: 30 day's post operative

  3. The Pittsburgh Sleep Quality Index

    To monitor sleeping habits

    Time frame: 4 weeks and 6 weeks post operative

  4. Knee Society Score

    Patient reported outcome

    Time frame: 4 weeks post operative

  5. KOOS-12 Knee Survey

    Patient reported outcome

    Time frame: 6 weeks post operative

  6. The Veterans Rand 12-Item Health Survey

    Patient reported outcome

    Time frame: 6 weeks post operative

07

Study locations

1 of 1 sites recruiting
  • Colorado Joint Replacement
    Denver, Colorado 80210, United States
    Recruiting
    • Roseann Johnson · ContactRoseannJohnson@centura.org · 303-260-2940
    • Jason Jennings, MD · Principal investigator
    • Douglas Dennis, MD · Sub investigator
    • Todd Miner, MD · Sub investigator
    • Charlie Yang, MD · Sub investigator
    • Mauricio Mejia, MD · Sub investigator
08

References and documents

Publications

  • Hannon CP, Calkins TE, Li J, Culvern C, Darrith B, Nam D, Gerlinger TL, Buvanendran A, Della Valle CJ. The James A. Rand Young Investigator's Award: Large Opioid Prescriptions Are Unnecessary After Total Joint Arthroplasty: A Randomized Controlled Trial. J Arthroplasty. 2019 Jul;34(7S):S4-S10. doi: 10.1016/j.arth.2019.01.065. Epub 2019 Feb 4. PubMed 30799266 ↗
  • Jennings JM, Williams MA, Levy DL, Johnson RM, Eschen CL, Dennis DA. Has Self-reported Marijuana Use Changed in Patients Undergoing Total Joint Arthroplasty After the Legalization of Marijuana? Clin Orthop Relat Res. 2019 Jan;477(1):95-100. doi: 10.1097/CORR.0000000000000339. PubMed 30794232 ↗
  • Hickernell TR, Lakra A, Berg A, Cooper HJ, Geller JA, Shah RP. Should Cannabinoids Be Added to Multimodal Pain Regimens After Total Hip and Knee Arthroplasty? J Arthroplasty. 2018 Dec;33(12):3637-3641. doi: 10.1016/j.arth.2018.07.027. Epub 2018 Aug 3. PubMed 30170713 ↗
  • Hayes MJ, Brown MS. Legalization of medical marijuana and incidence of opioid mortality. JAMA Intern Med. 2014 Oct;174(10):1673-4. doi: 10.1001/jamainternmed.2014.2716. No abstract available. PubMed 25156148 ↗
  • Heng M, McTague MF, Lucas RC, Harris MB, Vrahas MS, Weaver MJ. Patient Perceptions of the Use of Medical Marijuana in the Treatment of Pain After Musculoskeletal Trauma: A Survey of Patients at 2 Trauma Centers in Massachusetts. J Orthop Trauma. 2018 Jan;32(1):e25-e30. doi: 10.1097/BOT.0000000000001002. PubMed 29257781 ↗
  • Khelemsky Y, Goldberg AT, Hurd YL, Winkel G, Ninh A, Qian L, Oprescu A, Ciccone J, Katz DJ. Perioperative Patient Beliefs Regarding Potential Effectiveness of Marijuana (Cannabinoids) for Treatment of Pain: A Prospective Population Survey. Reg Anesth Pain Med. 2017 Sep/Oct;42(5):652-659. doi: 10.1097/AAP.0000000000000654. PubMed 28796754 ↗
  • Chan MH, Knoepke CE, Cole ML, McKinnon J, Matlock DD. Colorado Medical Students' Attitudes and Beliefs About Marijuana. J Gen Intern Med. 2017 Apr;32(4):458-463. doi: 10.1007/s11606-016-3957-y. Epub 2017 Jan 17. PubMed 28097606 ↗
  • Cancienne JM, Patel KJ, Browne JA, Werner BC. Narcotic Use and Total Knee Arthroplasty. J Arthroplasty. 2018 Jan;33(1):113-118. doi: 10.1016/j.arth.2017.08.006. Epub 2017 Aug 17. PubMed 28887020 ↗
  • Menendez ME, Ring D, Bateman BT. Preoperative Opioid Misuse is Associated With Increased Morbidity and Mortality After Elective Orthopaedic Surgery. Clin Orthop Relat Res. 2015 Jul;473(7):2402-12. doi: 10.1007/s11999-015-4173-5. Epub 2015 Feb 19. PubMed 25694266 ↗
  • Morris BJ, Mir HR. The opioid epidemic: impact on orthopaedic surgery. J Am Acad Orthop Surg. 2015 May;23(5):267-71. doi: 10.5435/JAAOS-D-14-00163. PubMed 25911660 ↗
  • Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004 Sep;3(9):771-84. doi: 10.1038/nrd1495. PubMed 15340387 ↗
  • Fitzcharles MA, Hauser W. Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases. Curr Rheumatol Rep. 2016 Dec;18(12):76. doi: 10.1007/s11926-016-0625-5. PubMed 27832442 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Feb 2024, 48 months after the start.

Of 36 non-industry phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 48 months is above that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2020
First posted
Mar 6, 2020
StartActual
Feb 5, 2020
Primary completionEst.
Feb 5, 2024
CompletionEst.
Feb 5, 2025
Last update
Jan 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04298528
Lead sponsor
Colorado Joint Replacement
Responsible party
Jason Jennings (Orthopedic Surgeon, Colorado Joint Replacement) — Principal investigator
First posted
Mar 6, 2020
Start date
Feb 5, 2020
Primary completion
Feb 5, 2024 (estimated)
Completion
Feb 5, 2025 (estimated)
Last update
Jan 10, 2023

Study contacts

Rose Johnson
Contact
roseannjohnson@centura.org
3032602940
Jason M Jennings, MD DPT
principal investigator · Colorado Joint Replacement

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion